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Abstract
In previous linkage and genome-wide association studies we identified 17 susceptibility loci for
generalized vitiligo. By a second genome-wide association study, meta-analysis, and independent
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replication study, we have now identified 13 additional vitiligo-associated loci, including OCA2-
HERC2, a region of 16q24.3 containing MC1R, a region of chromosome 11q21 near TYR, several
immunoregulatory loci including IFIH1, CD80, CLNK, BACH2, SLA, CASP7, CD44, IKZF4,
SH2B3, and a region of 22q13.2 where the causal gene remains uncertain. Functional pathway
analysis shows that most vitiligo susceptibility loci encode immunoregulatory proteins or
melanocyte components that likely mediate immune targeting and genetic relationships among
vitiligo, malignant melanoma, and normal variation of eye, skin, and hair color.
In generalized vitiligo patches of depigmented skin and hair result from autoimmune
destruction of epidermal melanocytes1, epidemiologically associated with other autoimmune
diseases2. In previous linkage analyses and a genome-wide association study (GWAS1;
Supplementary Table 1), we identified 14 confirmed and 3 suggestive vitiligo susceptibility
loci3–5 in persons of non-Hispanic European (EUR) ancestry. Most encode
immunoregulatory proteins, and several are associated with other autoimmune diseases.
However, one, TYR, encodes tyrosinase, a key enzyme of melanin biosynthesis that likely
mediates immune targeting of melanocytes. Causal variation at TYR is inversely associated
with vitiligo and malignant melanoma6, suggesting vitiligo may be related to immune
surveillance of melanoma7.
To identify additional vitiligo susceptibility loci, we performed a second GWAS (GWAS2;
Supplementary Table 1), with meta-analysis of GWAS1 and GWAS2 (GWAS-MA) to
enhance statistical power. GWAS2 included 450 EUR generalized vitiligo cases and
genotype data from 3,182 EUR controls from the database of Genotypes and Phenotypes
(dbGaP). The GWAS-MA demonstrated improved significance of almost all significant loci
from GWAS1 (Supplementary Table 2) and suggestive association (P < 10−4 for multiple
SNPs across a region) of 24 novel loci (Supplementary Figure 1 and Supplementary Table
3), of which six achieved genome-wide significance (P < 5 × 10−8) (Table 1). At all 24
novel loci, we imputed genotypes using 1000 Genomes Project data, performed logistic
regression to identify independent association signals, and genotyped the most significant
SNPs at each locus (Supplementary Table 3) in an independent replication cohort of 1440
EUR cases and 1316 EUR controls. We then performed overall meta-analysis of GWAS1,
GWAS2, and the replication study, using conservative criteria for confirming association: (i)
nominal association in the replication study (P < 0.05), (ii) consistent high-risk alleles in
GWAS1, GWAS2, and the replication study, (iii) non-significant heterogeneity across all
three studies (P > 1.09 × 10−3), and (iv) overall combined genome-wide significance (P < 5
× 10−8).
As shown in Table 1, we confirmed association of vitiligo with 13 novel loci. Among the
most interesting, at chromosome 15q12–q13.1 the GWAS-MA showed suggestive
association of SNPs (nt 27886016–28392261) spanning OCA2 upstream to within HERC2
(Fig. 1), especially rs12913832 (P = 3.29 × 10−7) and imputed SNP rs1129038 (P = 3.23 ×
10−7) (r2 = 0.99). OCA2 is causal for oculocutaneous albinism type 2, encodes a
melanosomal membrane transporter8, and plays a major role in determining skin, hair, and
eye color. The replication study and overall meta-analysis confirmed association of both
rs1129038 (P = 3.91 × 10−8, OR 1.22) and rs12913832 (P = 3.81 × 10−8, OR 1.22) (Table
1). Furthermore, the SNP alleles that are low-risk for vitiligo are strongly associated with
gray/blue eye color9–11 and with elevated risk of malignant melanoma12,13, tagging a
founder variant within HERC2 that down-regulates transcription of the OCA2 allele in
cis11,14. OCA2 is thus analogous to TYR: both encode melanocyte antigens presented by
HLA-A*0215,16, for both vitiligo protection is associated with reduced functional protein,
and for both susceptibility to vitiligo and melanoma constitute genetic opposites7, perhaps
modulating immune surveillance for melanoma (Supplementary Fig. 2). Furthermore, we
Jin et al. Page 2
Nat Genet. Author manuscript; available in PMC 2012 December 01.
$watermark-text
$watermark-text
$watermark-text
predict that gray/blue eye color should be under-represented, and tan/brown eye color over-
represented, among vitiligo patients. To test this, we surveyed 1206 EUR vitiligo patients,
confirming both predictions: among vitiligo patients the prevalence of gray/blue eye color
(26.8%) was greatly reduced and tan/brown eye color (43.2%) greatly elevated compared to
both USA17 (P < 0.0001) and Australian18 (P < 0.0001) EUR individuals; Table 2).
Compared to persons with gray/blue eye color, the OR for vitiligo was 2.98 in persons with
tan/brown eye color and 2.25 in persons with green/hazel eye color, indicating additional
eye color genes besides OCA2 constitute risk loci for vitiligo, and indeed TYR is associated
both with vitiligo3 and with green/hazel eye color19.
At chromosome 16q24.3, the GWAS-MA showed complex association of SNPs spanning nt
89647951–90078022, particularly rs8049897 (P = 2.03 × 10−7) and imputed SNPs
rs9926296 (P = 4.34 × 10−11) and rs4785587 (P = 1.08 × 10−8) (Supplementary Fig. 3a),
confirmed by the replication study and overall meta-analysis (rs9926296 P = 1.82 × 10−13,
OR 0.79). The associated region contains 20 genes, notably including MC1R, encoding the
melanocortin receptor, a regulator of melanogenesis and minor vitiligo autoantigen,
associated with malignant melanoma and with skin and hair color20.
At 11q21, the GWAS-MA showed association with rs4409785 (nt 95311422) (P = 2.26 ×
10−10) and imputed SNP rs11021232 (P = 9.20 × 10−10) (Supplementary Fig. 3b), confirmed
by the replication study and overall meta-analysis (rs4409785 P = 1.57 × 10−13, OR 1.34).
These SNPs are located in a 559 kb region containing no known genes, approximately 6.28
Mb distal to TYR. These SNPs are not in linkage disequilibrium with TYR SNPs (r2=0), and
remain highly significant when conditioned on common causal TYR SNPs rs1042602 and
rs1126809. We speculate this region might harbor a regulatory element affecting TYR
transcription in cis.
Besides OCA2, MC1R, and the chromosome 11q21 locus, most vitiligo-associated loci
encode immunoregulatory proteins. At chromosome 2q24.2, the GWAS-MA showed
association with SNPs spanning nt 163076146–163154363, between IFIH1 and FAP,
particularly rs2111485 (P = 1.67 × 10−10) (Supplementary Fig. 3c), confirmed by the
replication study and overall meta-analysis (rs2111485 P = 4.91 × 10−15, OR 0.77). IFIH1
encodes an interferon-induced RNA helicase involved in antiviral innate immune
responses21, associated with type 1 diabetes22, Graves' disease23, multiple sclerosis24,
psoriasis25, and perhaps lupus26.
At 3q13.33, the GWAS-MA showed suggestive association of SNPs (nt 119276377–
119197379) spanning and upstream of CD80, particularly rs4330287 and imputed SNP
rs59374417 (both P = 3.97 × 10−7; r2 = 1.0) (Supplementary Fig. 3d), confirmed by the
replication study and overall meta-analysis (rs59374417 P = 3.78 × 10−10, OR 1.34). CD80
is a surface protein on activated B-cells, monocytes, and dendritic cells that co-stimulates T
cell priming27,28.
At 4p16.1, the GWAS-MA showed suggestive association of SNPs (nt 10702156–
10729386) upstream of CLNK, including rs16872571 (P = 2.50 × 10−7) and several imputed
SNPs, particularly rs11940117 (P = 9.00 × 10−8) (Supplementary Fig. 3e), confirmed by the
replication study and overall meta-analysis (rs16872572 P = 1.56 × 10−8, OR 1.21). CLNK
encodes mast cell immunoreceptor signal transducer, a positive regulator of immunoreceptor
signaling29.
At 6q15, the GWAS-MA showed suggestive association of SNPs (nt 90941239-91915693)
spanning BACH2, particularly rs3757247 (P = 2.14 × 10−5) (Supplementary Fig. 3f),
confirmed by the replication study and overall meta-analysis (P = 2.53 × 10−8, OR 1.20).
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BACH2 encodes a transcriptional repressor of B cells30, and is associated with type 1
diabetes31,32, celiac disease33, and Crohn's disease34.
At 8q24.22, the GWAS-MA showed suggestive association of SNPs (nt
133929917-133979872) spanning the TG/SLA locus, at which the two genes are
interdigitated and encoded on the opposite strands. Most significant were rs853308 (P = 1.14
× 10−6) and several imputed SNPs (Supplementary Fig. 3g), confirmed by the replication
study and overall meta-analysis (rs853308 P = 1.58 × 10−8, OR 1.20). TG encodes
thyroglobulin, while SLA encodes Src-like adaptor protein, a regulator of antigen receptor
signaling35. TG is associated with autoimmune thyroid disease36, which affects
approximately 17 percent of vitiligo patients2, suggesting association of rs853308 with
vitiligo might derive from patients with concomitant autoimmune thyroid disease. However,
stratification showed association of rs853308 with vitiligo derives both from patients with (P
= 2.43 × 10−3) and without (P = 3.98 × 10−7) autoimmune thyroid disease, with virtually
identical ORs in the two subgroups (1.20 and 1.19, respectively). Moreover, directly
comparing rs853308 in vitiligo patients with (N = 608) versus without (N = 2579)
autoimmune thyroid disease showed no difference (P = 0.94, OR 1.01). It is not apparent
what role thyroglobulin might play in vitiligo pathogenesis, suggesting association of
vitiligo with the TG/SLA locus may derive from SLA, rather than TG. SLA might likewise
account for reported association of TG with autoimmune thyroid disease36.
At 10q25.3, the GWAS-MA showed suggestive association of SNPs (nt
115439530-115492092) spanning CASP7, particularly rs3814231 (P = 1.20 × 10−5)
(Supplementary Fig. 3h), confirmed by the replication study and overall meta-analysis (P =
3.56 × 10−8, OR 0.81). CASP7 encodes caspase 7, an executioner protein of apoptosis and
inflammation37, associated with rheumatoid arthritis38, and suggested as a candidate gene
for IDDM17 in type 1 diabetes39.
At 11p13, the GWAS-MA showed association of SNPs (nt 35242907-35375280) spanning
portions of CD44 and SLC1A2, particularly rs736374 (P = 3.06 × 10−8) and rs10768122 (P
= 6.13 × 10−8) (Supplementary Fig. 3i), confirmed by the replication study and overall meta-
analysis (rs10768122 P = 1.78 × 10−9, OR 1.21). CD44 encodes a cell surface glycoprotein
with various functions, including a role in T cell development40, and is associated with
lupus41.
At 12q13.2, the GWAS-MA showed association with SNPs (nt 56369506-56535251) in a
region including IKZF4 (Supplementary Fig. 3j), particularly rs1701704 (P = 1.53 × 10−9)
and imputed SNP rs2456973 (P = 1.22 × 10−9), confirmed by the replication study and
overall meta-analysis (rs2456983 P = 2.75 × 10−14, OR 1.29). IKZF4 encodes a regulator of
T cell activation42, and is associated with type 1 diabetes43 and alopecia areata44.
At 12q24.12, the GWAS-MA showed association with SNPs (nt 111708458-112906415)
within and near SH2B3, particularly rs3184504 (P = 1.32 × 10−11) and imputed SNP
rs4766578 (P = 9.10 × 10−12), located downstream, within ATXN2 (Supplementary Fig.
3k). Many SNPs in this region achieved genome-wide significance, but logistic regression
analysis indicated all reflect a single association signal. The replication study and overall
meta-analysis confirmed association of both rs3184504 (P = 2.46 × 10−17, OR 0.76) and
rs4766578 (P = 3.54 × 10−18, OR 0.76). ATXN encodes Ataxin-2, and is causal for
spinocerebellar ataxia type 2. SH2B3 encodes adaptor protein LNK, regulating development
of both B and T cells45, and associated with type 1 diabetes46, celiac disease47, rheumatoid
arthritis48, multiple sclerosis49, and perhaps lupus25. SH2B3 thus seems more likely relevant
to vitiligo susceptibility than ATXN2.
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At 22q13.2, the GWAS-MA showed suggestive association with SNPs in a broad region (nt
41707054-42062822), particularly rs79008 (P = 1.44 × 10−6), upstream of TOB2, and
several imputed SNPs, including rs4822024 (P = 1.02 × 10−7), between ZC3H7B and TEF
(Supplementary Fig. 3l). The replication study and overall meta-analysis confirmed
association of both SNPs, greatest with rs4822024 (P = 6.81 × 10−10, OR 0.78). TOB2
encodes a regulator of cell cycle progression involved in T cell tolerance50. However, the
locus contains 12 genes, and assignment of TOB2 as causal remains uncertain.
Besides these 13 confirmed vitiligo-associated loci, an additional locus at 19p13.3 did not
quite achieve genome-wide significance. The GWAS-MA showed suggestive association of
SNPs (nt 4830628-4837557) spanning TICAM1, particularly rs6510827 (P = 6.98 × 10−6)
and imputed SNP rs811383825 (P = 1.49 × 10−5) (Supplementary Fig. 3m), with association
with rs6510827 confirmed by the replication study and near-significance in the overall meta-
analysis (P = 8.80 × 10−8, OR 1.19). TICAM1 encodes toll-like receptor adaptor molecule 1,
which mediates innate immune responses to viral pathogens51. SNPs at ten additional loci
that appeared suggestive in the GWAS-MA were not confirmed by the replication study
(Supplementary Table 3).
Altogether, the vitiligo susceptibility loci we identified account for approximately 10% of
vitiligo risk in EUR individuals, and about 18% of vitiligo heritability (h2 ~ 0.75). Most
encode immunoregulatory proteins or melanocyte proteins that likely mediate antigenic
triggering and immune targeting of melanocytes, and bioinformatic network analysis
indicated at least 26 comprise a functional network spanning from the melanocyte to the
immune system (Supplementary Fig. 4). Many vitiligo susceptibility loci are shared with
other autoimmune diseases, most sharing the same high-risk alleles, consistent with
epidemiological associations among these diseases (Supplementary Fig. 5). Functional
prediction of all genotyped and imputed missense and splice junction variants in all
confirmed non-MHC vitiligo loci (Supplementary Table 4) identified predicted deleterious
variants at PTPN22, IFIH1, SLA, CD44, TYR, OCA2, MC1R, UBASH3A, and C1QTNF6,
and for TYR two common variants, S192Y and R402Q, confer protection from vitiligo,
whereas HLA-A *02:01 confers risk6. Additional vitiligo susceptibility loci undoubtedly
remain undiscovered; nevertheless, the genes and pathways already identified provide
insights into vitiligo pathobiology, optimal use of existing treatments, and even novel
therapeutics.
METHODS
Subjects
GWAS1 has been described previously3. GWAS2 included 450 unrelated generalized
vitiligo patients (cases) of non-Hispanic/Latino European ancestry (EUR) from North
America and Europe, who met strict clinical criteria for generalized vitiligo52. Controls for
GWAS2 were 3182 EUR individuals not specifically known to have any autoimmune
disease or malignant melanoma, for whom genome-wide genotypes were obtained from the
database of Genotypes and Phenotypes (dbGaP; phs000092v1, phs000125v1, phs000138v2,
phs000168v1, and phs000206v3), or from the Illumina iControlDB. The replication study
included 1440 unrelated EUR generalized vitiligo cases and 1316 unrelated EUR controls
from North America and Europe, principally spouses of vitiligo patients from the GWAS2
study and the replication study itself. There was no overlap of cases and controls between
the GWAS1, GWAS2, and replication cohorts. Cases and controls provided clinical history
regarding vitiligo and other autoimmune diseases as described previously for GWAS13, and
controls having known relatives with vitiligo or reporting any known autoimmune diseases
or melanoma were excluded. Eye color was by self-report. Written informed consent was
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obtained from all study subjects. This study was approved by each institutional review board
and was conducted according to Declaration of Helsinki principles.
Genotyping and quality control
Genomic DNA was prepared from saliva specimens using a DNA self-collection kit per the
manufacturer's instructions (Oragene, DNA Genotek). For genome-wide genotyping, DNA
concentrations were assayed by both fluorescence staining (PicoGreen method, Invitrogen)
and ultraviolet A260 spectrophotometry (Nanodrop, Thermo Scientific). For genotyping
specific SNPs in the replication study, DNA concentrations were assayed by Nanodrop.
Genome-wide genotyping for GWAS2 cases was performed for 657,366 SNPs using
Illumina Human660W-Quad BeadChips per the manufacturer's instructions. GWAS2
controls obtained from dbGaP and Illumina iControlDB had been genotyped using Illumina
Human 610-Quad and Human 1Mv1 BeadChips. Genotyping of 46 SNPs in the replication
study was performed using a custom Illumina GoldenGate assay per the manufacturer's
instructions.
Quality control filtering of genome-wide genotype data in GWAS2 was carried out as
described for GWAS13 using Illumina GenomeStudio, version 3 and PLINK53, version
1.07. Cases were excluded on the basis of SNP call rates < 98.5% (N = 16), discordance
between reported and observed sex (N = 0), and/or inadvertent subject duplication (N = 0).
Beyond prior quality control procedures, controls were excluded on the basis of SNP call
rates < 95% (N = 0). Additional cases (N = 6) and controls (N = 356) were excluded on the
basis of cryptic relatedness based on pair-wise identity-by-descent estimation (Pi-hat > 0.05)
of the entire (GWAS1 + GWAS2) summary dataset, in which case the individual with lower
SNP call rate was excluded. SNPs were excluded on the basis of genotype missing rate ≥ 2%
overall (N = 97,301) in cases plus controls, observed minor allele frequency < 0.01 (N =
23,064), significant deviation (P < 10−5) from Hardy-Weinberg equilibrium in the control
dataset (N = 5,241), and/or significant difference (P < 10−5) in genotype missing rate in
cases versus controls (N = 35,939). Data for SNPs with P values < 10−15 were reviewed
with respect to genotype clusters and allele calls in cases, and minor allele frequency in
controls compared to data in public data sources, and were excluded if there were apparent
data quality problems (N = 2). To control for population stratification, we performed
principle components analysis using EIGENSOFT54, version 4.2, and excluded as outliers
cases (N = 10) and controls (N = 16) whose ancestry was ≥ 6 standard deviations from the
mean on one of the top ten eigenvectors.
In the replication study we successfully determined genotypes for 46 SNPs that showed
suggestive (P < 10−4) or significant P values in the genome-wide meta-analysis of GWAS1
and GWAS2, using a custom Illumina GoldenGate assay. SNP genotypes were subjected to
quality control filters similar to those in GWAS1 and GWAS2, as appropriate.
Statistical analyses
For GWAS2, after quality control filtering of subjects and SNP data and removal of genetic
outliers, we compared allele frequencies of the remaining 495,821 SNPs in the final 418
cases and 2810 controls using the unadjusted Cochran-Armitage trend test implemented in
PLINK53 and the adjusted Cochran-Armitage trend test implemented in EIGENSOFT54, in
which both phenotypes and genotypes of subjects were adjusted for ancestry using the top
ten eigenvectors. The unadjusted Cochran-Armitage trend tests and the adjusted Cochran-
Armitage trend tests yielded genomic inflation factors of 1.054 and 1.050, respectively,
indicating that residual population stratification was negligible. Odds ratios and 95%
confidence limits were calculated by logistic regression analysis by use of PLINK53.
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To fully assess association at the 24 novel suggestive loci, we imputed genotypes for each
locus using MaCH55, ver.1.0 based on patterns of haplotype variation in the 1000 Genomes
Project European ancestry samples (Release Aug 4, 2010). We retained imputed SNPs with
r2 > 0.3 and minor allele frequency > 0.01 for further analyses.
For the replication study, after quality control filtering, we compared allele frequencies for
genotyped SNPs in the remaining 1377 patients and 1284 controls using the Cochran-
Armitage trend test. Odds ratios and 95% confidence limits were calculated by logistic
regression analysis.
To obtain combined ORs and P values for GWAS1 and GWAS2, and for the combined
GWAS1, GWAS2, and replication studies, we performed meta-analysis using a Cochran-
Mantel-Haenszel test. A Breslow-Day test was used to test for heterogeneity of ORs of the
same SNP in different study cohorts.
Calculation of linkage disequilibrium between SNPs in regions of association was carried
out using Haploview56, version 4.2. As a test of the independent effect of a given locus
conditioned on the effect of another locus, we compared the fit of a model containing both
loci to a model containing only the conditioning locus, assuming a multiplicative genotypic
effect for the high-risk allele of each locus. Analyses were performed using STATA, version
10.0.
We estimated the contribution of known vitiligo susceptibility loci to the total variance in
vitiligo liability as the difference between the variance accounted for by all SNPs genome-
wide and the variance remaining after removing SNPs in known vitiligo susceptibility loci,
using GCTA57 to estimate the two components of variance. We estimated heritability of
vitiligo liability58,59 assuming a vitiligo prevalence in the EUR population of 0.003860 and
sibling risk 0.062.
Functional network analysis
To gain insights into potential functional relationships among proteins encoded by vitiligo
risk loci, we carried out functional interaction network analysis using the Search Tool for the
Retrieval of Interacting Genes (STRING) 9.061. Input data were all known vitiligo
susceptibility loci (including TICAM1, and selecting BTNL2 to represent the MHC class II
gene region3). In addition, we iteratively tested inclusion of all proteins encoded by genes in
the 16q24.3 and 22q13.2 association regions as well as FAM76B as potentially representing
the 11q21 association region as a means of possible gene identification.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Association of generalized vitiligo with SNPs in the OCA2-HERC2 region of chromosome
15q12–q13.1. Results of Cochran-Mantel-Haenszel meta-analysis of GWAS1 and GWAS2
data (GWAS-MA) for genotyped (black) and imputed (blue) SNPs on the y axis versus
chromosomal nucleotide position (GRCh37/hg19) on the x axis. Red circles indicate the
Cochran-Mantel-Haenszel P values from the GWAS1, GWAS2, and replication studies for
rs12913832 and rs1129038 (see Table 1). Arrows indicate gene positions and transcriptional
orientation.
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Table 1
GWAS meta-analysis, replication, and overall meta-analysis of novel generalized vitiligo susceptibility loci
GWAS-MA (GWAS 1 +
GWAS 2)
Replication study Overall Meta-Analysis (GWAS 1 + GWAS 2+ replication
study)
Chr SNP Positional Candidate gene RA EA EAF P OR TREND P OR P OR Breslow-Day P
2q24.2 rs2111485 IFIH1 G A 0.38 1.67 × 10−10 0.77 7.26 × 10−6 0.78 4.91 × 10−15 0.77 1.14 × 10−2
rs1990760 T C 0.38 2.00 × 10−9 0.78 1.18 × 10−5 0.78 9.33 × 10−14 0.78 2.83 × 10−2
3q13.33 rs59374417 CD80 A C 0.13 3.97 × 10−7 1.33* 3.02 × 10−4 1.33 3.78 × 10−10* 1.34* 5.41 × 10−1
rs4330287 C A 0.13 3.97 × 10−7 1.33 5.90 × 10−4 1.31 7.80 × 10−10 1.33 5.80 × 10−1
4p16.1 rs11940117 CLNK C T 0.47 9.00 × 10−8 1.24* 3.03 × 10−2 1.13 1.96 × 10−8* 1.20* 3.99 × 10−1
rs16872571 T C 0.56 2.50 × 10−7 1.23 1.54 × 10−2 1.16 1.56 × 10−8 1.21 7.31 × 10−1
6q15 rs3757247 BACH2 G A 0.47 2.14 × 10−5 1.18 2.91 × 10−4 1.22 2.53 × 10−8 1.20 5.16 × 10−1
8q24.22 rs853308 SLA A G 0.48 1.14 × 10−6 1.21 3.24 × 10−3 1.18 1.58 × 10−8 1.20 8.33 × 10−1
10q25.3 rs3814231 CASP7 G A 0.25 1.20 × 10−5 0.81 8.80 × 10−4 0.81 3.56 × 10−8 0.81 9.77 × 10−1
rs4353229 T C 0.25 1.32 × 10−* 0.84 9.10 × 10−4 0.81 4.35 × 10−7 0.83 9.18 × 10−1
11p13 rs736374 CD44 G A 0.38 3.06 × 10−8 1.25 1.45 × 10−2 1.15 3.41 × 10−9 1.22 1.51 × 10−1
rs10768122 A G 0.41 6.13 × 10−8 1.24 5.74 × 10−3 1.17 1.78 × 10−9 1.22 1.66 × 10−1
11q21 rs4409785 TYR regulation T C 0.19 2.26 × 10−10 1.36 1.58 × 10−4 1.30 1.57 × 10−13 1.34 4.63 × 10−1
rs11021232 T C 0.20 9.20 × 10−10 1.35 3.23 × 10−5 1.32 1.91 × 10−13* 1.34* 6.07 × 10−1
12q13.2 rs1701704 IKZF4 A C 0.35 1.53 × 10−9 1.28 4.44 × 10−6 1.30 3.19 × 10−14 1.29 8.09 × 10−1
rs2456973 A C 0.35 1.22 × 10−9 1.28 4.97 × 10−6 1.30 2.75 × 10−14* 1.29* 8.16 × 10−1
12q24.12 rs3184504 SH2B3 T C 0.49 1.32 × 10−11 0.76 2.31 × 10−7 0.75 2.46 × 10−17 0.76 1.17 × 10−1
rs4766578 T A 0.48 9.10 × 10−12 0.76 4.07 × 10−8 0.73 3.54 × 10−18* 0.76* 1.01 × 10−1
15q12-13.1 rs1129038 OCA2-HERC2 T C 0.27 3.23 × 10−7 1.26 2.06 × 10−2 1.14 3.91 × 10−8* 1.22* 4.66 × 10−1
rs12913832 G A 0.27 3.29 × 10−7 1.26 2.01 × 10−2 1.14 3.81 × 10−8 1.22 4.71 × 10−1
16q24.3 rs4785587 MC1R G A 0.49 1.08 × 10−8 0.80 1.44 × 10−4 0.81 6.35 × 10−12* 0.80* 7.98 × 10−1
rs9926296 A G 0.46 4.34 × 10−11 0.77 5.16 × 10−4 0.82 1.82 × 10−13* 0.79* 1.35 × 10−1
19p13.3† rs6510827 TICAM1 C T 0.41 6.98 × 10−6 1.20 3.87 × 10−3 1.17 8.80 × 10−8 1.19 6.37 × 10−1
22q13.2 rs4822024 TOB2 G A 0.21 1.02 × 10−7 0.76 1.54 × 10−3 0.81 6.81 × 10−10* 0.78* 2.00 × 10−1
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GWAS-MA (GWAS 1 +
GWAS 2)
Replication study Overall Meta-Analysis (GWAS 1 + GWAS 2+ replication
study)
Chr SNP Positional Candidate gene RA EA EAF P OR TREND P OR P OR Breslow-Day P
rs79008 G A 0.19 1.44 × 10−6 0.78 1.13 × 10−3 0.79 6.19 × 10−9 0.78 7.95 × 10−1
This table reports data for newly identified vitiligo susceptibility loci that had P < 1 × 10−4 in the GWAS meta-analysis (GWAS-MA; GWAS1 + GWAS2), P < 0.05 in the replication study, P < 5 × 10−8
in the overall meta-analysis (GWAS1 + GWAS2 + replication study), with consistent effect allele and non-significant Breslow-Day heterogeneity statistics for the ORs across all three studies (P > 1.09 ×
10−3). RA, reference allele; EA, effect allele; EAF, effect allele frequency (among all cases and controls).
*
Imputed from 1000 Genomes Project data.
†
The association signal at 19p13.3 does not quite achieve the criterion for genome-wide significance but is included for completeness
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Table 2
Eye color among Non-Hispanic/Latino European-derived vitiligo patients versus normal individuals
Eye color USA/Canada/UK vitiligo patients (%) USA European-derived normals17 (%) Australian European-derived
normals18 (%)
Blue/gray 323 (26.8) 1856 (51.6) 1314 (46.1)
Green/hazel 362 (30.0) 788 (21.7) 789 (27.7)
Tan/brown 521 (43.2) 968 (26.7) 749 (26.3)
P-value - <0.0001 <0.0001
P values were obtained by chi-square distribution comparison of the number of individuals with tan/brown, green/hazel, and blue/gray eyes
between the vitiligo patient and indicated normal groups.
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